Anti-clotting treatment apixaban outperforms Lovenox in study

03/4/2010 | Reuters

Apixaban beat standard treatment Lovenox in preventing blood clots without increasing the risk of bleeding during a late-stage trial in patients who underwent knee surgery. Apixaban is a product of Pfizer and Bristol-Myers Squibb, which plan to submit the drug for European approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care